Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Cancer Survivors At Greater Risk Of Birth Complications; Special Monitoring Needed
Survivors of childhood cancer run particular risks when pregnant and should be closely monitored, the 25th annual conference of the European Society of Human Reproduction and Embryology heard today (Wednesday 1 July). Dr. Sharon Lie Fong, of the Department of Obstetrics and Gynaecology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands, said that, although such women may have conceived spontaneously and considered themselves to be perfectly healthy, their deliveries should always take place in a hospital.
generic viagra online
Eurand Successfully Completes Registration Procedure For Paracetamol ODT 250 And 500 Mg In The European Union
Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced that the Dutch Medicines Evaluation Board (MEB) informed the Company that the Decentralized Procedure (DCP) for registration of Paracetamol 250 and 500 mg Orodispersible Tablets (ODT) in several EU countries has been successfully completed.
News of the day
Single Dose Palonosetron Prevents Emesis Induced By Chemotherapy In Non Hodgkin's Lymphoma Patients
New data presented at the EHA (European
Oncology

AVI BioPharma, Inc. To Present At 7th Annual Biodefense Vaccines & Therapeutics Conference In Washington, D.C.

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced that Patrick Iversen, Ph.D., Senior Vice President of Strategic Alliances, will present at the upcoming 7th Annual Biodefense Vaccines & Therapeutics conference taking place in Washington, D.C. Dr. Iversen will present on Monday, June 15, as part of a pre-conference symposium on "Developments in Biodefense Technology Platform." He will be a featured speaker in a session titled "Building Technology Platforms to Array Against Multiple Threats," where he will discuss the utility of AVI"s RNA-based drugs against biological threats, including Ebola and Marburg viruses. AVI has begun to evaluate the rapid mobilization of RNA-based drugs against positive and negative strand RNA viruses. This analysis includes target optimization, avoidance of drug resistance and the relative advantages of virus-specific and host immune response-specific therapeutics to both improve host protection and reduce disease. Information about the conference can be found here. AVI BioPharma

Team Building Melbourne commented:

A great article on conference according to me on one of the best topic. I appreciate with the content written in the article

17.05.2012


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009